Gapping up
In reaction to strong earnings/guidance: GIII +8.2%, WEN +4.5%, (guidance and announces $1.4 bln buyback program), NVMI +3.3%, AMBA +2.3%, BSM +1.7%
M&A news: SNCR +21.8% (reports the company is exploring a sale)
Select Bio/pharma names showing strength: OCLS +3.1%, OCLR +2.7%, GALE +2.4%, RGLS +2%, OXGN +2%, ONTY +1.5%, STEM +1.4%, .
Other news: LPTH +10% (provided update on its new infrared product line), SYN +9.6% (announces initial data that support the development of a platform of therapeutics designed to protect the microbiome from carbapenems), ARDX +7.5% (entered into a termination agreement with AstraZeneca (AZN)), MNOV +5.3% (FDA has granted it orphan drug designation to MN-166 for Krabbe Disease), OPXA +4.5% (disclosed that it has requested an additional 180-day grace period to regain compliance with NASDAQ's minimum bid price requirement), ORIG-5.1% (announced offering of common stock), AGEN +4.3% (announces that Merck has extended its collaborative research term), BIOC +4.2% (Enters Clinical Collaboration with Sarah Cannon Research Institute ), RDHL +3.3% (provides update on development pipeline), TASR +3.1% (body camera stories out overnight; London to roll out 20k body cameras), RXII +3% (granted notice of allowance for patent covering lead compound, RXI-109, for use in the eye), HRTX +2.8% (Chairman Kevin C Tang discloses purchase of 150k shares at average price of $20.62), RYAAY +2.8% (rpted May traffic), PSTI +2.2% (receives grant from Israel's MOE to market PLX Cell Therapy in Japan), RMTI +1.7% (filed for $200 mln offering of common stock), DENN +1.1% (favorable commentary on Tuesday's Mad Money)
Analyst comments: ZLTQ +3.7% (upgraded to Buy from Neutral at Goldman), GPRO +3.3% (target raised to $75 from $70 at JP Morgan), LNKD +2.8% (added to U.S. Equity Analyst Focus List at JP Morgan), NICE +1.7% (upgraded to Overweight from Neutral at JP Morgan), FTR +1.7% (upgraded to Buy from Neutral at DA Davidson), CIEN +1.1% (initiated with a Buy at Nomura), BX +1% (initiated with an Overweight at Piper Jaffray), TWX +0.9% (initiated with an Outperform at Credit Suisse), CAT +0.8% (initiated with a Buy at Societe Generale), AMZN +0.8% (initiated with a Outperform at Credit Suisse), SGNT +0.6% (initiated with a Strong Buy at Raymond James), ANET +0.5% (initiated with a Buy at Nomura
)
In reaction to strong earnings/guidance: GIII +8.2%, WEN +4.5%, (guidance and announces $1.4 bln buyback program), NVMI +3.3%, AMBA +2.3%, BSM +1.7%
M&A news: SNCR +21.8% (reports the company is exploring a sale)
Select Bio/pharma names showing strength: OCLS +3.1%, OCLR +2.7%, GALE +2.4%, RGLS +2%, OXGN +2%, ONTY +1.5%, STEM +1.4%, .
Other news: LPTH +10% (provided update on its new infrared product line), SYN +9.6% (announces initial data that support the development of a platform of therapeutics designed to protect the microbiome from carbapenems), ARDX +7.5% (entered into a termination agreement with AstraZeneca (AZN)), MNOV +5.3% (FDA has granted it orphan drug designation to MN-166 for Krabbe Disease), OPXA +4.5% (disclosed that it has requested an additional 180-day grace period to regain compliance with NASDAQ's minimum bid price requirement), ORIG-5.1% (announced offering of common stock), AGEN +4.3% (announces that Merck has extended its collaborative research term), BIOC +4.2% (Enters Clinical Collaboration with Sarah Cannon Research Institute ), RDHL +3.3% (provides update on development pipeline), TASR +3.1% (body camera stories out overnight; London to roll out 20k body cameras), RXII +3% (granted notice of allowance for patent covering lead compound, RXI-109, for use in the eye), HRTX +2.8% (Chairman Kevin C Tang discloses purchase of 150k shares at average price of $20.62), RYAAY +2.8% (rpted May traffic), PSTI +2.2% (receives grant from Israel's MOE to market PLX Cell Therapy in Japan), RMTI +1.7% (filed for $200 mln offering of common stock), DENN +1.1% (favorable commentary on Tuesday's Mad Money)
Analyst comments: ZLTQ +3.7% (upgraded to Buy from Neutral at Goldman), GPRO +3.3% (target raised to $75 from $70 at JP Morgan), LNKD +2.8% (added to U.S. Equity Analyst Focus List at JP Morgan), NICE +1.7% (upgraded to Overweight from Neutral at JP Morgan), FTR +1.7% (upgraded to Buy from Neutral at DA Davidson), CIEN +1.1% (initiated with a Buy at Nomura), BX +1% (initiated with an Overweight at Piper Jaffray), TWX +0.9% (initiated with an Outperform at Credit Suisse), CAT +0.8% (initiated with a Buy at Societe Generale), AMZN +0.8% (initiated with a Outperform at Credit Suisse), SGNT +0.6% (initiated with a Strong Buy at Raymond James), ANET +0.5% (initiated with a Buy at Nomura
)